Mason Passes Legislation Redefining Epinephrine Delivery Products

SPRINGFIELD, Ill. — State Rep. Joyce Mason, D-Gurnee, passed a measure updating epinephrine-related legislation to reflect medical advancements in epinephrine administration, including FDA-approved products like nasal sprays.

“Most of us are familiar with epinephrine auto-injectors, commonly referred to as Epi-pens. Even if you don’t have a life-threatening allergy, you probably know someone who carries an EpiPen with them. It’s a big needle, and it’s definitely intimidating, especially for kids,” said Mason. “EpiPens also have very specific storage needs and relatively short shelf lives. Now, there are new options that are less invasive, less expensive, have fewer storage regulations, and may just save more lives in an emergency. This bill ensures parents and patients have options when it comes to epinephrine delivery, and that our first responders, our schools and our caregivers are equipped with the tools and training needed to assist in an allergy attack, while avoiding needle injections when possible.”

Mason filed House Bill 3454 in 2025 with the intention to change terminology to include all forms of epinephrine delivery. The nasal spray form of epinephrine delivery (Neffy) was FDA approved in 2024 and has been available since. Dissolvable epinephrine strips are in late stages of development, but have yet to be approved. Both products increase the convenience of epinephrine delivery, while avoiding the invasive, painful process of EpiPen needle injections. The effectiveness of the live-saving medication remains the same across all delivery products. 

House Bill 3454 also outlines the process of training and equipping law enforcement officers, school nurses and healthcare professionals with any and all epinephrine delivery devices.

“Even small things like language changes can have a big impact. And this bill is a perfect example. By changing the terminology in epinephrine legislation, the process of epinephrine delivery can accurately reflect the rapid developments of this medication, while still prioritizing the safety and health of those with life-threatening allergies,” said Mason.

Mason’s House Bill 3454 passed unanimously out of the House chamber Wednesday.